cms.bioaccessla.com

Category: Uncategorized

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, now set by statutory review clocks (Disposición 7516/25 for drug studies, Disposición 969/1997 for device studies), is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (drug-study review clocks, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost and regulator throughput (for device studies, a legal maximum of 90 business days from filing under Disposición 969/1997, versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols early: Disposición 7516/25 governs drug studies, and device studies fall under Disposición 969/1997, which gives ANMAT up to 90 business days from filing to decide. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. For drug studies, Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), sets business-day review clocks for clinical pharmacology protocols, with ethics committee review running in parallel to ANMAT agency review rather than in sequence. Device studies follow a different rule: Disposición 969/1997, the regime for medical technology clinical studies, gives ANMAT up to 90 business days from filing to decide, with the clock paused while objections are open. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    The bioaccess® sample budget puts a first-in-human study in Latin America at about $430K for 20 subjects with a minimally invasive device and about $1.32M for 10 subjects with a surgical implant (illustrative, not a quote; see bioaccessla.com/sample-budget-fih-trial-latin-america). For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25 (drug studies), Disposición 969/1997 (device studies), the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol (under Disposición 969/1997 for a device study, or Disposición 7516/25 for a drug study) runs the two reviews in parallel rather than in sequence, so the Argentine arm can begin generating bridge data without waiting on the U.S. file. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a parallel Argentine arm into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. Disposición 7516/25 is operative for drug studies, and device studies run under Disposición 969/1997. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Five Questions Every Medtech Founder Must Ask A CRO Before Signing The MSA

    Five Questions Every MedTech Founder Must Ask a CRO Before Signing the MSA

    Five Questions Every MedTech Founder Must Ask a CRO Before Signing the MSA

    Published by bioaccess®® | May 2026

    The Most Expensive Vendor Decision You Will Make Before Your Series B

    The master services agreement you sign with a CRO at the first-in-human stage is not just a vendor contract. It is a commitment to a timeline, a data architecture, a regulatory strategy, and — in ways most founders do not fully price until they are inside the engagement — a bet on whether that organization has ever actually done this before.

    Most MedTech founders spend more time negotiating SaaS subscription pricing than interrogating the operational fitness of the CRO they are about to trust with their first human study. CROs are practiced at presenting capability decks that are both technically accurate and structurally misleading: yes, they have run first-in-human studies. The questions are how many, how recently, where, and with what kind of dedicated team.

    Getting this wrong is costly in ways that do not appear on the MSA. A generalist CRO that applies Phase 3 operational logic to a 10-patient FIH study produces delays and data packages that do not travel well to FDA. The five questions below are designed for use in an actual vendor conversation, written so that an organization built specifically for first-in-human work answers all five without hesitation and a generalist CRO with Phase 3 heritage struggles on at least three. The contrast is the diagnostic.

    Question 1: “What percentage of your active studies are first-in-human?”

    This question cuts through every capability deck. Most large CROs list “Phase 1-4” as an integrated capability — and that is technically accurate. ICON, Syneos Health, and Parexel all offer first-in-human services. What their materials do not disclose is the proportion of revenue, headcount, and operational attention that FIH commands relative to their Phase 2-4 and post-market portfolio. According to the ICON plc 2024 Annual Report, the company’s growth narrative is anchored in Phase 2-4 and functional service offerings. Syneos Health’s service model is similarly configured around integrated biopharmaceutical solutions at scale — not the 10-patient device feasibility study a seed-stage founder needs to execute.

    The operational implication: when FIH is a small fraction of a CRO’s active portfolio, the project managers on your study are people who primarily run Phase 3 logistics. They understand protocol compliance and site management at the multi-site scale. What they may not have is the judgment that comes from running dozens of first human exposures — the real-time risk calculus of dose escalation, the site selection nuances that matter when you have ten patients rather than three hundred, and the FDA communication posture that FIH-specific experience produces.

    The follow-up question matters equally: “Who on your team has personally run more than ten first-in-human studies from device selection through first patient in?” An organization that cannot surface a dedicated FIH unit with named individuals and verifiable track records has not built FIH as an operational discipline.

    Red flag: Any CRO that cannot give you a clean percentage of active studies that are first-in-human has not built FIH as an operational core. It is a line item in a service menu. A CRO for which FIH is the only practice answers this question with a number above 90 percent — because there is nothing else on the portfolio.

    Question 2: “What is your documented median time from IND/IDE submission to site initiation in your primary jurisdiction?”

    Timeline is not a soft preference. It is a capital efficiency variable. Every month between IND/IDE equivalent submission and first patient in is a month of runway consumed and a month of competitive exposure while your device sits in regulatory review.

    The documented benchmark for ethics committee approval in Latin American FIH programs — for organizations with established site relationships and a mature submission infrastructure — is 4 to 8 weeks. In Colombia, where the regulatory framework has been shaped by over a decade of FIH execution, approval instances as fast as 15 to 18 days have been recorded. This is the result of site-level relationships, submission formatting that ethics committees recognize, and a regulatory team with institutional familiarity with the FIH protocol type.

    The U.S. comparison is not subtle. The average IRB/EC cycle in the United States for a novel device IDE study runs 6 to 12 months from submission to site initiation when you account for FDA review, IRB submission, site contracting, and institutional compliance review. In the EU, a 6-month horizon from IDE equivalent to first patient in remains the conservative planning assumption most regulatory counsel will give you.

    Illustrative Ethics Approval Timeline Comparison
    Jurisdiction Documented Range Basis
    LATAM (Colombia, established sites) 4-8 weeks (fastest: 15-18 days) bioaccess® operational track record, 2010-present
    United States (IDE pathway) 6-12 months (submission to site initiation) FDA CDRH IDE review statistics
    EU (CTR pathway) 3-9 months (submission to site initiation) EMA Clinical Trials Regulation implementation data

    When you ask this question, you are asking for documented median performance, not a best case. An organization that cannot answer with data has not been measuring what matters.

    Question 3: “Have you produced a data package accepted by FDA from a non-U.S. trial in the past 36 months?”

    The most persistent misconception among U.S. device founders about outside the United States clinical data is that FDA will not accept it. This misconception is expensive, because it leads founders to dismiss LATAM and other OUS execution pathways as regulatory dead ends when the regulatory framework explicitly accommodates foreign clinical data.

    21 CFR 312.120 permits FDA acceptance of foreign clinical data when the trial was conducted in accordance with Good Clinical Practice and under a protocol FDA would consider adequate and well-controlled. 21 CFR 812.28 extends parallel provisions to device studies, explicitly addressing acceptance of data from foreign investigations in support of IDE and PMA submissions.

    A first-in-human study conducted in Colombia, Brazil, or Peru under a GCP-compliant protocol, with a data architecture designed to meet FDA standards, can generate the foundational data package that supports a U.S. IDE submission. The LATAM study is not a workaround. It is a legitimate regulatory pathway.

    Executing it correctly requires a CRO that has actually done it. “We could produce FDA-compatible data” is not the same as “we have produced FDA-accepted data from an OUS trial in the past three years.” Ask for the latter. Ask for the regulatory outcomes. Ask whether the data traveled to FDA and what the response was.

    A CRO that has never navigated 21 CFR 312.120 or 812.28 in practice — regardless of what their regulatory affairs team says in a capabilities presentation — is asking you to be their learning case at the stage where you cannot afford that tuition.

    Question 4: “What is your per-patient cost range for a 10-to-15 patient FIH study in your primary jurisdiction?”

    Per-patient cost for a FIH study is the single most compressed way to understand the financial architecture of a CRO engagement before you are inside one. Cost transparency at the proposal stage is not a courtesy — it is a due diligence requirement.

    The bioaccess® sample budget puts a first-in-human study in Latin America at about $430K for 20 subjects with a minimally invasive device and about $1.32M for 10 subjects with a surgical implant (illustrative, not a quote; see bioaccessla.com/sample-budget-fih-trial-latin-america). That differential — roughly 59 percent lower cost per patient in LATAM — reflects the structural economics of clinical site operations in markets where investigator compensation, institutional overhead, and support cost structures differ materially from U.S. and EU norms.

    On a 10-patient FIH study, the arithmetic is direct: U.S. The difference — $250,000 to $400,000 — is material capital at the seed or pre-Series A stage. It extends runway. It funds the follow-on safety cohort. It covers FDA pre-submission preparation. It is the difference between a founder who enters their Series A with FIH data and remaining runway, and one who spent it all to generate the same data in a U.S. site.

    A CRO that deflects to “it depends on the protocol” without offering a range for a standard FIH configuration has either not run enough FIH studies to have a stable cost model, or does not want you comparing numbers before you have signed.

    Question 5: “Can you execute an EFS submission and manage a concurrent OUS FIH study under a single operational team?”

    The FDA’s Early Feasibility Study program is one of the most underutilized regulatory tools available to U.S. MedTech founders. According to the FDA Early Feasibility Study Program, the EFS pathway is designed for early-stage devices where clinical data is needed to inform device design — precisely the stage at which a FIH study occurs. The MDIC 10-Year EFS Journey analysis documented that approximately 70 percent of EFS submissions receive FDA response within 30 days — a timeline that makes concurrent OUS and U.S. enrollment operationally feasible within the same funding window.

    The strategic logic of concurrent execution is about data architecture, not just speed. A LATAM FIH study generating safety and early efficacy signals in parallel with a U.S. EFS enrollment produces a richer, more FDA-defensible data package than either study would generate independently. The LATAM cohort contributes patient volume and diverse population data; the U.S. cohort generates data with direct site-level FDA familiarity. Together, they build an IDE submission or PMA dataset from a position of evidence rather than assumption.

    Executing this dual-track strategy requires a CRO that can manage both pathways under a coherent operational structure — not two separate vendor relationships requiring a founder as the integration layer. The question diagnoses whether a CRO has built the capacity to hold both regulatory tracks in a single team, or is offering LATAM execution on one hand and a referral to a U.S. partner on the other.

    The U.S. EFS pathway and a concurrent LATAM FIH study are not competing strategies. They are the same strategy, executed in parallel, by an organization that understands both regulatory environments as a single integrated operation.

    How to Use This Checklist

    These five questions are not adversarial. They are clarifying. A CRO that has built its operations around first-in-human work will not find them uncomfortable — they will find them efficient, because the answers surface quickly from an organization that lives in this space every day.

    Use the questions in the initial capabilities conversation, before you have a proposal on the table and a timeline pressure that makes switching feel costly. The moment to evaluate operational fit is before you have signed anything, not after you are inside a study running six months behind the timeline the capabilities deck implied.

    • What percentage of your active studies are first-in-human?
    • What is your documented median time from IND/IDE equivalent submission to site initiation?
    • Have you produced a data package accepted by FDA from a non-U.S. trial in the past 36 months?
    • What is your per-patient cost range for a 10-to-15 patient FIH study?
    • Can you execute an EFS submission and manage a concurrent OUS FIH study under a single operational team?

    If the answers satisfy all five questions, you are talking to a CRO that may be able to run your first human study competently. If they do not, you have learned something before the signature, not after.

    Ready to Run the Evaluation?

    bioaccess® works with MedTech founders at every stage of FIH preparation — from regulatory strategy through first patient in. If you want to talk through your specific program against these five criteria:

    Sources